Optimizing your API strategy to deliver desired results
Section 1: Why API Strategy Is Corporate Strategy The Active Pharmaceutical Ingredient is not a line item in a chemistry […]
Optimizing your API strategy to deliver desired results Read Post »
February 2018
Generic Drug Markets: U.S. vs. Europe. Prices, Volumes, IP Strategy, and the $445 Billion Savings Gap
Why This Comparison Matters Now The generic pharmaceutical industry generated $445 billion in U.S. system savings in 2023 alone, according
US Biosimilars: The Complete Barrier Map for IP Teams, Payers, and Portfolio Managers
Key Takeaways (Executive Summary) Part I: The BPCIA Framework — Why ‘Abbreviated’ Is a Misnomer What the Biologics Price Competition
US Biosimilars: The Complete Barrier Map for IP Teams, Payers, and Portfolio Managers Read Post »
The Biosimilar Paradox: 2026 Market Report on Systemic Challenges, Policy Collisions, and the Future of Biologic Competition
Executive Summary As of January 2026, the United States biosimilars market stands at a critical juncture, characterized by a fundamental
